Emerging studies highlight its immunosuppressive effects on CD8+ T cells via the CD155/TIGIT signaling pathway in hepatocellular carcinoma, indicating that TIGIT-expressing T cells exhibit compromised functioning against tumors (Zhang et al., 2020). The gene discussed is TIGIT; the disease is hepatocellular carcinoma.